04:03 AM EDT, 10/22/2025 (MT Newswires) -- Viridian Therapeutics ( VRDN ) said late Tuesday it has priced an underwritten public offering of 11.4 million common shares at $22 per share for total expected gross proceeds of $251.4 million.

The underwriters have been granted a 30-day option to purchase up to about 1.7 million additional shares.

Net proceeds will be used to fund commercial activities, research and development, working capital and general corporate purposes, the company said.

Closing of the offering is expected to occur on or about Oct. 23, subject to customary closing conditions.